Pro‐inflammatory SASP (IL‐1, IL‐6, CXCL8, TNFα) [10] and expression of pro‐angiogenic factors (VGEFA, GDF15) [11, 12] suppress anti‐tumor immunity, whereas some types of SASP can activate anti‐tumor immunity by augmenting tumor antigen presentation (Interferon family; IFN), cytotoxic T cell infiltration (CXCL9, CXCL10, CXCL11) [13], and activation of NK cells and T cells (IL‐2, MICB) [14, 15]. The gene discussed is IL2; the disease is neoplasm.